Smith & Nephew (SN) Competitors

GBX 981
+16.60 (+1.72%)
(As of 04/26/2024 ET)

SN vs. CTEC, HIK, HCM, HLN, MXCT, NIOX, CREO, EKF, NCYT, and IUG

Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Haleon (HLN), MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), EKF Diagnostics (EKF), Novacyt (NCYT), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical" sector.

Smith & Nephew vs.

ConvaTec Group (LON:CTEC) and Smith & Nephew (LON:SN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.

66.7% of ConvaTec Group shares are owned by institutional investors. Comparatively, 55.6% of Smith & Nephew shares are owned by institutional investors. 20.2% of ConvaTec Group shares are owned by insiders. Comparatively, 0.2% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Smith & Nephew had 1 more articles in the media than ConvaTec Group. MarketBeat recorded 2 mentions for Smith & Nephew and 1 mentions for ConvaTec Group. Smith & Nephew's average media sentiment score of 1.34 beat ConvaTec Group's score of 0.65 indicating that ConvaTec Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ConvaTec Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Smith & Nephew
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Smith & Nephew received 202 more outperform votes than ConvaTec Group when rated by MarketBeat users. However, 66.54% of users gave ConvaTec Group an outperform vote while only 61.83% of users gave Smith & Nephew an outperform vote.

CompanyUnderperformOutperform
ConvaTec GroupOutperform Votes
352
66.54%
Underperform Votes
177
33.46%
Smith & NephewOutperform Votes
554
61.83%
Underperform Votes
342
38.17%

ConvaTec Group has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 1.9%. Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 3.1%. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

ConvaTec Group currently has a consensus price target of GBX 307.17, suggesting a potential upside of 19.15%. Smith & Nephew has a consensus price target of GBX 1,362.50, suggesting a potential upside of 38.89%. Given ConvaTec Group's higher possible upside, analysts plainly believe Smith & Nephew is more favorable than ConvaTec Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConvaTec Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Smith & Nephew
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Smith & Nephew has higher revenue and earnings than ConvaTec Group. Smith & Nephew is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ConvaTec Group£2.14B2.47£130.30M£0.055,156.00
Smith & Nephew£5.55B1.55£263M£0.244,087.50

ConvaTec Group has a net margin of 6.08% compared to ConvaTec Group's net margin of 4.74%. Smith & Nephew's return on equity of 7.89% beat ConvaTec Group's return on equity.

Company Net Margins Return on Equity Return on Assets
ConvaTec Group6.08% 7.89% 4.79%
Smith & Nephew 4.74%5.02%4.27%

Summary

ConvaTec Group beats Smith & Nephew on 13 of the 20 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Sign up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SN vs. The Competition

MetricSmith & NephewMedical Devices IndustryMedical SectorLON Exchange
Market Cap£8.58B£1.93B£4.88B£1.65B
Dividend Yield3.13%2.44%2.91%10.51%
P/E Ratio4,087.50234.03223.541,965.52
Price / Sales1.55208.362,337.49373,216.16
Price / Cash18.6814.7247.1025.93
Price / Book1.644.194.762.54
Net Income£263M£40.39M£103.77M£183.66M
7 Day Performance2.00%0.10%0.73%1.56%
1 Month Performance-5.99%-3.00%-8.17%9.53%
1 Year Performance-23.86%45.49%3.72%9.68%

Smith & Nephew Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTEC
ConvaTec Group
1.7119 of 5 stars
GBX 286.60
+1.5%
GBX 307.17
+7.2%
+18.6%£5.88B£2.14B5,732.0010,136News Coverage
Positive News
Gap Down
HIK
Hikma Pharmaceuticals
0.5963 of 5 stars
GBX 1,819
+0.1%
GBX 2,068.75
+13.7%
+8.6%£4.04B£2.88B2,714.939,100Analyst Report
News Coverage
HCM
HUTCHMED
0 of 5 stars
GBX 290
+5.1%
N/A+19.3%£2.48B£838M2,900.001,988News Coverage
High Trading Volume
HLN
Haleon
0.11 of 5 stars
GBX 332.80
+0.6%
GBX 356
+7.0%
-4.8%£30.38B£11.30B3,025.4525,408
MXCT
MaxCyte
0 of 5 stars
GBX 323
+2.5%
N/A-22.4%£336.34M£41.29M-1,113.79143
NIOX
NIOX Group
0.6188 of 5 stars
GBX 66.80
+1.5%
GBX 77
+15.3%
+44.6%£282.40M£36.80M3,340.0092High Trading Volume
CREO
Creo Medical Group
0 of 5 stars
GBX 34.75
flat
N/A+46.5%£125.61M£29.27M-315.91279News Coverage
EKF
EKF Diagnostics
0 of 5 stars
GBX 27.60
+0.4%
N/A+0.4%£125.23M£52.61M2,760.00356News Coverage
Gap Up
NCYT
Novacyt
0 of 5 stars
GBX 68
+1.5%
N/A+33.7%£48.03M£7.87M-188.89120
IUG
Intelligent Ultrasound Group
0 of 5 stars
GBX 8.50
-5.6%
N/A-37.2%£27.78M£10.26M-850.0065

Related Companies and Tools

This page (LON:SN) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners